ClinicalTrials.govpublic full text
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
hormone receptor positive her-2 negative breast cancer, metastatic breast cancer, recurrent breast cancer, hormone receptor positive (hr+), human epidermal growth factor receptor 2 negative (her2-), interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 867522
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.